Data show that diabetes is a disease caused by the combination of genetic and environmental factors with abnormal glucose metabolism as the main manifestation, mainly due to insufficient insulin secretion by human islet β cells or islet dysfunction
.
In recent years, the research of diabetes has made great progress, whether it is the management concept of diabetes, or the monitoring and treatment technology has been developed
rapidly.
At the same time, the diabetes drug market is also growing
.
According to data, the global diabetes drug market size reached 73.
9 billion US dollars in 2021, while China's diabetes drug market reached 74.
6 billion yuan, and it is expected to reach 100 billion yuan in
2024.
In addition, data show that in 2021, the sales scale of diabetes drugs in China's three major terminal markets exceeded 60 billion yuan
.
Under the huge demand for drugs, domestic pharmaceutical companies have also continuously strengthened the layout
of the diabetes drug market.
For example, "innovative drug brother" Hengrui Pharmaceutical has also stormed the diabetes drug market
.
It is reported that on January 13, the Center for Drug Evaluation (CDE) of the State Medical Products Administration of China announced that Shengdi Pharmaceutical, a subsidiary of Hengrui Pharmaceutical, has submitted new drug marketing applications for repagliptin metformin tablets (I.
) and repagliptin metformin tablets (II.
) and has been accepted
.
According to public information, this is a fixed-dose combination preparation of dipeptidyl peptidase IV.
(DPP-4) inhibitor repagliptin phosphate and metformin hydrochloride developed by Hengrui Pharmaceutical
.
It is used to treat type 2 diabetes
in adults.
Among them, repagliptin is a dipeptidyl peptidase IV.
(DPP-4) inhibitor, and its new drug application for the treatment of type 2 diabetes is under CDE review and approval
.
DPP-4 inhibitors can promote the release of insulin by pancreatic islet β cells while inhibiting the secretion of glucagon by pancreatic islet α cells, thereby increasing endogenous insulin levels and glucose uptake
by body tissues.
Metformin, another component in the compound, can reduce hepatic glucose production, reduce glucose absorption in the intestine, and improve the body's insulin sensitivity
by increasing glucose intake and utilization by peripheral tissues.
Through the two different mechanisms of action of repagliptin and metformin, it is expected to achieve better hypoglycemic effect and improve patient medication compliance
.
Hengrui Pharmaceutical has been in the field of diabetes for many years, and its class 1 new drug proline hengliflozin tablets was approved for marketing on December 31, 2021, which is a domestic innovative SGLT2 inhibitor
.
It is reported that Hengliflozin is about to participate in medical insurance negotiations and is expected to start in 2023
.
In May 2022, Hengrui Pharmaceutical submitted a marketing application
for the new drug Henggliflozin metformin sustained-release tablets.
In addition, the company also has long-acting insulin INS068, long-acting insulin/GLP-1 compound preparation HR17031, ultra-fast insulin HR011408\GLP-1 analogue Noli glycopeptide and other hypoglycemic products under development
.
The industry expects that in the future, the field of diabetes will become a new driving force
for the growth of Hengrui Pharmaceutical's innovative drugs.
It is understood that Hengrui Pharmaceutical has continuously increased investment in innovation in recent years to promote drug innovation and research and development
.
Data show that from 2018 to 2021, Hengrui Pharmaceutical's R&D investment increased from 2.
67 billion yuan to 6.
203 billion yuan, and the proportion of R&D investment in revenue increased from 15.
3% to 24%.
Since 2021, the company has capitalized part of the phase III clinical R&D expenses, and the R&D expenses still reached 5.
94 billion, and the R&D expense ratio reached 22.
9%.
The industry said that under large-scale R&D investment, Hengrui Pharmaceutical's innovative drugs have achieved rich results, and the company has now approved 12 innovative drug products for marketing, maintaining an efficient rhythm
of an average of two innovative drugs approved for marketing every year since 2018.
At present, the company still has 5 innovative drugs in the NDA stage, more than 10 innovative drugs in phase III research and development, and it is expected to maintain the approval rhythm of 3 or more innovative drugs approved every year in the future, and the performance of the innovative drug sector has sufficient momentum for accelerated growth
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
